September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
November 2023 in “Circulation” Minoxidil can cause a rare but serious condition that leads to fluid buildup around the heart and drug-induced lupus.
January 2024 in “Tropical Journal of Pharmaceutical Research” Minoxidil liniment is effective in treating hair loss in women.
22 citations
,
June 1991 in “Clinical Therapeutics” Oxiconazole nitrate cream is effective and safe for treating various fungal skin infections.
15 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Spironolactone effectively treats female pattern hair loss with few side effects.
10 citations
,
October 2018 in “Dermatologic Therapy” The lotion with equol, dihomo-γ-linolenic acid, and propionyl-l-carnitine was effective in reducing hair loss in men and women.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
January 2026 in “Figshare” Low-dose oral minoxidil improves hair loss and quality of life for women, despite mild unwanted hair growth.
June 2026 in “Frontiers in Medicine” Spironolactone has the most side effects, including serious risks, while eplerenone and finerenone mainly affect the heart, kidneys, and metabolism.
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
5 citations
,
February 2013 in “Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology” A teenager lost hair due to fluoxetine and sertraline, but it grew back after stopping these drugs and switching to a different one.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” June 2025 in “British Journal of Dermatology” Low-dose oral minoxidil is increasingly used by dermatologists in the UK and Ireland to treat various hair loss conditions.
1 citations
,
May 2022 in “Journal of Drugs in Dermatology” Low-dose naltrexone and platelet-rich plasma can regrow hair in lichen planopilaris.
75 citations
,
June 2019 in “International Journal of Molecular Sciences” Costunolide may have multiple health benefits, including promoting hair growth and protecting against cancer and diabetes, but more research is needed.
February 2026 in “PubMed” Low-dose oral minoxidil improves hair loss and quality of life for women, despite mild side effects.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
January 2023 in “Journal of clinical pharmacy and therapeutics” Isoliensinine, a natural compound, prevents stress-related hair greying by blocking a specific receptor on hair cells.
December 2024 in “Brazilian Journal of Development” Farmácias de manipulação precisam melhorar o controle de qualidade do Minoxidil.
January 2011 in “Dialnet (Universidad de la Rioja)” The spray makes hair styling easier and less greasy, improving minoxidil use.
34 citations
,
May 2017 in “Lasers in Surgery and Medicine” Combining low-level light therapy and minoxidil 5% is more effective for female hair loss than using either treatment alone.
17 citations
,
October 2013 in “Der Hautarzt”
5 citations
,
October 2020 in “Brain Research Bulletin” Etifoxine, an anxiety drug, can lessen brain inflammation and cognitive issues in mice, partly by increasing production of protective brain steroids.
8 citations
,
November 2022 in “Cureus” Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.
May 2026 in “Reactions Weekly”
19 citations
,
May 1979 in “Archives of internal medicine” Minoxidil effectively lowers blood pressure and initially increases plasma renin activity without raising aldosterone levels.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.